Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?

Sáfadi, Marco Aurélio Palazzi

doi:10.1590/0103-05822014322

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 13 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during RSV season 4 . The groups with a higher risk of severe respiratory disease caused by RSV are premature infants, children with chronic lung disease of prematurity, immunosuppressed children and children suffering from heart conditions, especially those with hemodynamic consequences 1 .…”

Section: Introductionmentioning

confidence: 99%